Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-GPC3-CAR-T lymphocytes TAK-102

A preparation of T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for glypican-3 (GPC3), with potential immunostimulating and antineoplastic activities. Upon administration, anti-GPC3-CAR-T lymphocytes TAK-102 specifically targets and binds to GPC3-expressing tumor cells, resulting in tumor cell lysis. GPC3, a heparan sulfate proteoglycan and a member of the glypican family, is overexpressed on certain tumor cell types while minimally expressed on normal, healthy cells; GPC3 plays an important role in cellular proliferation and differentiation.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-GPC3 CAR T cells TAK-102
CAR T cells TAK-102
glypican-3-specific CAR T cells TAK-102
Code name:TAK 102
TAK-102
TAK102
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search